Mga Batayang Estadistika
| LEI | 549300AHOLZBHHYFWP04 |
| CIK | 1213037 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cardiff Oncology, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 28, 2025 |
As filed with the U.S. Securities and Exchange Commission on August 28, 2025 As filed with the U.S. Securities and Exchange Commission on August 28, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cardiff Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 27-2004382 (State or other jurisdiction IRS Employer of incorporation or organi |
|
| August 28, 2025 |
CARDIFF ONCOLOGY, INC. STOCK OPTION GRANT AGREEMENT FOR NONSTATUTORY STOCK OPTIONS CARDIFF ONCOLOGY, INC. STOCK OPTION GRANT AGREEMENT FOR NONSTATUTORY STOCK OPTIONS Cardiff Oncology, Inc., a Delaware corporation (the “Company”) does hereby grant to Guobao Zhang (the “Optionee”), an option (the “Option”) that is NOT intended to qualify as an incentive stock option pursuant to Section 422(b) of the Internal Revenue Code, to purchase shares of the Company’s common stock (“Stock”) |
|
| August 28, 2025 |
CARDIFF ONCOLOGY, INC. STOCK OPTION GRANT AGREEMENT FOR NONSTATUTORY STOCK OPTIONS CARDIFF ONCOLOGY, INC. STOCK OPTION GRANT AGREEMENT FOR NONSTATUTORY STOCK OPTIONS Cardiff Oncology, Inc., a Delaware corporation (the “Company”) does hereby grant to Roger Sidhu (the “Optionee”), an option (the “Option”) that is NOT intended to qualify as an incentive stock option pursuant to Section 422(b) of the Internal Revenue Code, to purchase shares of the Company’s common stock (“Stock”) i |
|
| August 28, 2025 |
Calculation of Filing Fee Tables Form S-8 (Form Type) Cardiff Oncology, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Co |
|
| July 29, 2025 |
EMBARGOED FOR 4:07 EST 7/29 Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004) – Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) – – Early PFS data show a trend favoring 30mg onvansertib dose arm vs. |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CARDIFF |
|
| July 29, 2025 |
Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update - Appointed Dr. |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2025 Cardiff Oncology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35558 27-2004382 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| July 29, 2025 |
JULY 29, 2025 CRDF-004 Trial Update 1st Line RAS-mutated mCRC JULY 29, 2025 CRDF-004 Trial Update 1st Line RAS-mutated mCRC Forward-looking statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 Cardiff Oncology, Inc. |
|
| June 17, 2025 |
Employment Agreement dated June 16, 2025 by and between Dr. Roger Sidhu and Cardiff Oncology, Inc. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made and entered into effective as of June 16, 2025 (the “Effective Date”), by and between Roger Sidhu (the “Executive”) and Cardiff Oncology, Inc. |
|
| June 17, 2025 |
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC – Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development – – Company will hold a conference call |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 Cardiff Oncology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35558 27-2004382 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 12, 2025 |
CARDIFF ONCOLOGY, INC. 11055 Flintkote Ave. San Diego, CA 92121 CARDIFF ONCOLOGY, INC. 11055 Flintkote Ave. San Diego, CA 92121 May 12, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Lauren Hamill Re: Cardiff Oncology, Inc. Registration Statement on Form S-3 Filed February 27, 2025 File No. 333-285327 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the S |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CARDIFF |
|
| May 8, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 8, 2025 As filed with the U.S. Securities and Exchange Commission on May 8, 2025 Registration No. 333-285327 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cardiff Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 27-2004382 (State or other jurisdiction IRS Employer of in |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 Cardiff Oncology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35558 27-2004382 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 8, 2025 |
Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Expanded intellectual property portfolio with second patent covering treatment of all bev-naïve patients, including RAS-mutated and RAS wild-type mCRC, across all lines of therapy - - Cash and investments of $79. |
|
| April 30, 2025 |
NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 29, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| February 27, 2025 |
As filed with the U.S. Securities and Exchange Commission on February 27, 2025 As filed with the U.S. Securities and Exchange Commission on February 27, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cardiff Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 27-2004382 (State or other jurisdiction IRS Employer of incorporation or orga |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-35558 CARDIFF ONCOLOGY, |
|
| February 27, 2025 |
CARDIFF ONCOLOGY, INC. INSIDER TRADING COMPLIANCE PROGRAM Effective Date: January 1, 2016 Amended: September 13, 2016 Revision 02 Date: December 5, 2018 Revsision 03 Date: January 28, 2020 Revision 04 Date: May 8, 2020 CARDIFF ONCOLOGY, INC. |
|
| February 27, 2025 |
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer (“mCRC”) clinical trial (CRDF-004) - - Priced oversubscribed $40 million underwritten registered direct offering with participation from new and existing healthcare dedicated investors - - Issuance of new patent with claims for the use of onvansertib for treating KRAS-mut mCRC - - Cash and equivalents of $91. |
|
| February 27, 2025 |
Exhibit 4.3 CARDIFF ONCOLOGY, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.1 Designation and Terms of Securities 4 Section 2.2 Form of Securities and Trustee’s Certificate 5 Se |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Cardiff Oncology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35558 27-2004382 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 27, 2025 |
Form of Subordinated Indenture Exhibit 4.4 CARDIFF ONCOLOGY, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certific |
|
| February 27, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) CARDIFF ONCOLOGY, INC. |
|
| January 6, 2025 |
AMENDED AND RESTATED BY-LAWS OF CARDIFF ONCOLOGY, INC. ARTICLE I Corporate Offices 1. Registered Office. The registered office of Cardiff Oncology, Inc. shall be fixed in the corporation’s Certificate of Incorporation, as the same may be amended from time to time. 2. Other Offices. The corporation’s Board of Directors (the “Board”) may at any time establish other offices at any place or places whe |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 03, 2025 Cardiff Oncology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35558 27-2004382 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 17, 2024 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| December 11, 2024 |
15,384,619 Shares of Common Stock Cardiff Oncology, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-264148 PROSPECTUS SUPPLEMENT (To Prospectus Dated April 25, 2022) 15,384,619 Shares of Common Stock Cardiff Oncology, Inc. We are offering 15,384,619 shares of our common stock. Our common stock trades on The Nasdaq Capital Market under the symbol “CRDF.” On December 9, 2024, the last reported sale price of our common stock on The Nasdaq Capita |
|
| December 10, 2024 |
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering Exhibit 99.1 Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering SAN DIEGO, December 10, 2024 – Cardiff Oncology, Inc. (Nasdaq: CRDF) (“Cardiff Oncology” or the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the pricing of an underwritten offering of 15,384,61 |
|
| December 10, 2024 |
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial - Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control arm - - In the experimental arms, 30mg dose of onvansertib demonstrated a higher ORR compared to 20mg dose of onvansertib (64% vs. |
|
| December 10, 2024 |
Underwriting Agreement dated as of December 10, 2024 Exhibit 1.1 CARDIFF ONCOLOGY, INC. 15,384,619 Shares of Common Stock UNDERWRITING AGREEMENT December 10, 2024 TD Securities (USA) LLC As Representative of the several Underwriters 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: 1. Introductory. Cardiff Oncology, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this Agreement, to the severa |
|
| December 10, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 Cardiff Oncology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35558 27-2004382 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 10, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 Cardiff Oncology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35558 27-2004382 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 10, 2024 |
DECEMBER 10, 2024 CRDF-004 Trial 1st Line RAS-mutated mCRC Initial Data Release DECEMBER 10, 2024 CRDF-004 Trial 1st Line RAS-mutated mCRC Initial Data Release Forward-looking statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| November 7, 2024 |
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update - Published positive Phase 2 trial results of onvansertib in combination with FOLFIRI and bev in second-line KRAS mutant mCRC in the peer-reviewed Journal of Clinical Oncology - - Initial data readout from first-line RAS-mutated mCRC randomized CRDF-004 trial expected by the end of 2024- - Projected runway with current cash resources into Q1 2026 - SAN DIEGO, November 7, 2024 - Cardiff Oncology, Inc. |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2024 Cardiff Oncology, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35558 27-2004382 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CAR |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Cardiff Oncology, Inc. |
|
| August 8, 2024 |
Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update - Initial readout from first-line RAS-mut. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CARDIFF |
|
| July 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) CARDIFF ONCOLOGY, INC. |
|
| July 1, 2024 |
As filed with the U.S. Securities and Exchange Commission on July 1, 2024 As filed with the U.S. Securities and Exchange Commission on July 1, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cardiff Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 27-2004382 (State or other jurisdiction IRS Employer of incorporation or organizat |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 Cardiff Oncology, Inc. |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| June 3, 2024 |
AMENDMENT TO BY-LAWS Adopted on May 30, 2024 AMENDMENT TO BY-LAWS Adopted on May 30, 2024 The By-laws of Cardiff Oncology, Inc. |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 Cardiff Oncology, Inc. |
|
| May 2, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 Cardiff Oncology, Inc. |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CARDIFF |
|
| May 2, 2024 |
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update - In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated mCRC lead program - - In RAS wild-type mCRC, preclinical data presented at AACR demonstrated onvansertib’s antitumor act |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 8, 2024 |
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study RAS-mutated mCRC - In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and growth - - Enhanced clinical efficacy signal in |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 Cardiff Oncology, Inc. |
|
| March 27, 2024 |
Employee Stock Option Agreement dated January 30, 2023 by and between CARDIFF ONCOLOGY, INC. STOCK OPTION GRANT AGREEMENT FOR NONSTATUTORY STOCK OPTIONS Cardiff Oncology, Inc., a Delaware corporation (the “Company”) does hereby grant to Fairooz Kabbinavar (the “Optionee”), an option (the “Option”) that is NOT intended to qualify as an incentive stock option pursuant to Section 422(b) of the Internal Revenue Code, to purchase shares of the Company’s common stock (“St |
|
| March 27, 2024 |
Employee Stock Option Agreement dated June 20, 2023 by and between Cardiff CARDIFF ONCOLOGY, INC. STOCK OPTION GRANT AGREEMENT FOR NONSTATUTORY STOCK OPTIONS Cardiff Oncology, Inc., a Delaware corporation (the “Company”) does hereby grant to Shumet Hailu (the “Optionee”), an option (the “Option”) that is NOT intended to qualify as an incentive stock option pursuant to Section 422(b) of the Internal Revenue Code, to purchase shares of the Company’s common stock (“Stock”) |
|
| March 27, 2024 |
Employee Stock Option Agreement dated January 31, 2022 by and between CARDIFF ONCOLOGY, INC. STOCK OPTION GRANT AGREEMENT FOR NONSTATUTORY STOCK OPTIONS Cardiff Oncology, Inc., a Delaware corporation (the “Company”) does hereby grant to Robert Milford (the “Optionee”), an option (the “Option”) that is NOT intended to qualify as an incentive stock option pursuant to Section 422(b) of the Internal Revenue Code, to purchase shares of the Company’s common stock (“Stock” |
|
| March 27, 2024 |
Employee Stock Option Agreement dated December 2,2021 by and between CARDIFF ONCOLOGY, INC. STOCK OPTION GRANT AGREEMENT FOR NONSTATUTORY STOCK OPTIONS Cardiff Oncology, Inc., a Delaware corporation (the “Company”) does hereby grant to Chuck Monahan (the “Optionee”), an option (the “Option”) that is NOT intended to qualify as an incentive stock option pursuant to Section 422(b) of the Internal Revenue Code, to purchase shares of the Company’s common stock (“Stock”) |
|
| March 27, 2024 |
As filed with the U.S. Securities and Exchange Commission on March 27, 2024 As filed with the U.S. Securities and Exchange Commission on March 27, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cardiff Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 27-2004382 (State or other jurisdiction IRS Employer of incorporation or organiz |
|
| March 27, 2024 |
Employee Stock Option Agreement dated July 24,2023 by and between Cardiff CARDIFF ONCOLOGY, INC. STOCK OPTION GRANT AGREEMENT FOR NONSTATUTORY STOCK OPTIONS Cardiff Oncology, Inc., a Delaware corporation (the “Company”) does hereby grant to Rananand Arun Subramanian (the “Optionee”), an option (the “Option”) that is NOT intended to qualify as an incentive stock option pursuant to Section 422(b) of the Internal Revenue Code, to purchase shares of the Company’s common sto |
|
| March 27, 2024 |
Employee Stock Option Agreement dated December 2, 2021 by CARDIFF ONCOLOGY, INC. STOCK OPTION GRANT AGREEMENT FOR NONSTATUTORY STOCK OPTIONS Cardiff Oncology, Inc., a Delaware corporation (the “Company”) does hereby grant to Nancy Sherman (the “Optionee”), an option (the “Option”) that is NOT intended to qualify as an incentive stock option pursuant to Section 422(b) of the Internal Revenue Code, to purchase shares of the Company’s common stock (“Stock”) |
|
| March 27, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) CARDIFF ONCOLOGY, INC. |
|
| March 27, 2024 |
Employee Stock Option Agreement dated January 10, 2022 by and between CARDIFF ONCOLOGY, INC. STOCK OPTION GRANT AGREEMENT FOR NONSTATUTORY STOCK OPTIONS Cardiff Oncology, Inc., a Delaware corporation (the “Company”) does hereby grant to Tod Smeal (the “Optionee”), an option (the “Option”) that is NOT intended to qualify as an incentive stock option pursuant to Section 422(b) of the Internal Revenue Code, to purchase shares of the Company’s common stock (“Stock”) in |
|
| March 27, 2024 |
Employee Stock Option Agreement dated July 12, 2021 by and between Cardiff CARDIFF ONCOLOGY, INC. STOCK OPTION GRANT AGREEMENT FOR NONSTATUTORY STOCK OPTIONS Cardiff Oncology, Inc., a Delaware corporation (the “Company”) does hereby grant to James Levine (the “Optionee”), an option (the “Option”) that is NOT intended to qualify as an incentive stock option pursuant to Section 422(b) of the Internal Revenue Code, to purchase shares of the Company’s common stock (“Stock”) |
|
| February 29, 2024 |
AGENDA Q4 2023 Financial Results and ONSEMBLE Trial Data risks related to business interruptions, including the outbreak of COVID-19 coronavirus and cyber- attacks on our information technology infrastructure, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. |
|
| February 29, 2024 |
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC - New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients - - Company discontinued the ONSEMBLE trial in August 2023 to shift focus of clinical development program to first-line RAS-mutated mCRC in agreement with the FDA - - Company will hold a conference call today at 4:30 p. |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-35558 CARDIFF ONCOLOGY, |
|
| February 29, 2024 |
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update - First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution from Pfizer Ignite - - Interim topline data from first-line RAS-mutated mCRC trial is expected in mid-2024 - - New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients - - Cash and equivalents of $75 million as of December 31, 2023, projected runway into Q3 2025 - - Company will hold a conference call today at 4:30 p. |
|
| February 29, 2024 |
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004) - Phase 2 trial in patients with RAS-mutated mCRC will evaluate onvansertib plus SoC versus SoC alone in the first-line setting - - Pfizer Ignite is responsible for the clinical execution of the trial - - Initial topline results expected in mid-2024 – - Company will hold a conference call today at 4:30 p. |
|
| February 29, 2024 |
Cardiff Oncology, Inc. CLAWBACK POLICY Adopted September 20, 2023 Exhibit 97 Cardiff Oncology, Inc. CLAWBACK POLICY Adopted September 20, 2023 I.Purpose and Scope The Board believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this clawback policy (the |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 Cardiff Oncology, Inc. |
|
| February 6, 2024 |
CRDF / Cardiff Oncology, Inc. / ACORN BIOVENTURES, L.P. - CARDIFF ONCOLOGY, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cardiff Oncology, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 14147L108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Cardiff Oncology, Inc. |
|
| January 8, 2024 |
a991ex010824 JAN UARY 2 0 2 4 Company Overview The Onvansertib Opportunity First-in-Class PLK1 inhibitor • Onvansertib • FDA • FDA Robust clinical data in 2L KRAS-mut mCRC • 73% ~25% • 15 month ~8 month Pfizer • Pfizer • Pfizer We expect clinical data from our 1st line RAS-mutated mCRC trial in mid-2024 Runway with current cash extends into 2025 Human metastatic colorectal cancer (mCRC) tumors gro |
|
| November 2, 2023 |
Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update - Advance to first-line RAS-mutated metastatic colorectal cancer (mCRC) for lead program based on positive clinical and preclinical data and guidance from FDA - - Expanded relationship with Pfizer, which will provide clinical execution of new Phase 2 randomized first-line mCRC trial of onvansertib + standard-of-care ( |
|
| November 2, 2023 |
NOVEMBER 2, 2023 Q3 2023 Financial Results and Business Update 2 Forward-looking statements CERTAIN STATEMENTS IN THIS PRESENTATION ARE FORWARD-LOOKING within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Cardiff Oncology, Inc. |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CAR |
|
| September 26, 2023 |
a991ex09262023 Pancreatic Cancer and Small Cell Lung Cancer Program Updates Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) • • • Small Cell Lung Cancer (SCLC) • Onvansertib SPECIFICITYPROPERTIES • • • Line of Therapy Ph2 Ph3 Combination with:Trial IIT* Targets with oncogenic alterations Targets without oncogenic alterations * ROS1 estimated eligible patients presented in Turning Point Therapeutics’ corporate presentation May 2022 slide 6 (NSCLC disease incidence in the US of 140k of which 2% of patients harbor ROS1 translocation). |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2023 Cardiff Oncology, Inc. |
|
| September 26, 2023 |
Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Cardiff Oncology, Inc. |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CARDIFF |
|
| August 9, 2023 |
Development Agreement between Cardiff Oncology, Inc. and Pfizer, Inc. dated June 30, 2023 Confidential [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. |
|
| August 9, 2023 |
Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update - New lead program in first-line RAS-mutated metastatic colorectal cancer (mCRC) and expanded Pfizer relationship; interim topline data expected in mid-2024 - - Advance to first-line mCRC follows strong signal from new clinical and preclinical findings and guidance from FDA, and represents an increased market opportunity - - Cash, cash equivalents, and short-term investments of approximately $89. |
|
| August 9, 2023 |
CARDIFF ONCOLOGY, INC. CERTIFICATE OF ELIMINATION OF SERIES B, SERIES C, SERIES D AND SERIES E CONVERTIBLE PREFERRED STOCK Pursuant to Section 151(g) of the General Corporation Law of the State of Cardiff Oncology, Inc. (the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), DOES HEREBY CERTIFY: FIRST. Pursuant |
|
| August 7, 2023 |
Exhibit 99.1 AU GU ST 7 , 2 0 2 3 mCRC Program Update and Clinical Development Plan PFIZER We expect clinical data from our 1st line RAS-mutated mCRC trial in mid-2024 mCRC clinical development program agreed with FDA • • • • • • 5 3 Annual eligible U.S. patients (’000s)* 15 12 40 0 50 23 48 Line of Therapy Ph2 Ph3 Investigator-initiated trials Trial Combination with: CLINICAL FINDINGS FROM 2L Ph |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 Cardiff Oncology, Inc. |
|
| August 7, 2023 |
Exhibit 99.2 Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship - Advance to first-line RAS-mutated mCRC follows the strong signal from new clinical and preclinical data, and agreement with FDA - - First-line mCRC represents substantial increase in patient impact and market opportunity over second-line - - Pfizer Ignite will be r |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 Cardiff Oncology, Inc. |
|
| July 24, 2023 |
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, July 24, 2023 /PRNewswire/ - Cardiff Oncology, Inc. |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 Cardiff Oncology, Inc. |
|
| June 20, 2023 |
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, June 20, 2023 /PRNewswire/ - Cardiff Oncology, Inc. |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 Cardiff Oncology, Inc. |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CARDIFF |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Cardiff Oncology, Inc. |
|
| May 4, 2023 |
Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with KRAS/NRAS-mutated Metastatic Colorectal Cancer (mCRC) Introduced full membership of Scientific Advisory Board (SAB) Announced appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer Cash, cash equivalents, and short-term investments of approximately $97 million as of March 31, 2023, projected runway into 2025 SAN DIEGO, May 4, 2023 - Cardiff Oncology, Inc. |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Cardiff Oncology, Inc. |
|
| March 2, 2023 |
Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update Phase 1b/2 trial in lead KRAS-mutated metastatic colorectal cancer (mCRC) program continues to show our lead candidate onvansertib demonstrates an objective response rate, durability and progression-free survival that substantially exceed those seen in historical control trials Strengthened leadership team with appointments of Fairooz Kabbinavar, MD, FACP, as CMO, Tod Smeal, Ph. |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 Cardiff Oncology, Inc. |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-35558 CARDIFF ONCOLOGY, |
|
| February 14, 2023 |
CRDF / Cardiff Oncology Inc / CAXTON CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 2, 2023 |
Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer Brings world class capabilities and deep expertise in colorectal cancer and other solid tumor indications to advance the clinical development of onvansertib Served as the lead investigator for two practice-changing trials of bevacizumab (Avastin®) combinations leading to the approval of bevacizumab in metastatic colorectal cancer (mCRC)1,2 SAN DIEGO, February 2, 2023 – Cardiff Oncology, Inc. |
|
| February 2, 2023 |
EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made and entered into effective as of February , 2023 (the “Effective Date”), by and between Fairooz Kabbinavar, MD, FACP (the “Executive”) and Cardiff Oncology, Inc. |
|
| February 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023 Cardiff Oncology, Inc. |
|
| January 26, 2023 |
CRDF / Cardiff Oncology Inc / ACORN BIOVENTURES, L.P. - CARDIFF ONCOLOGY, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cardiff Oncology, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 14147L108 (CUSIP Number) ** (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| January 26, 2023 |
CRDF / Cardiff Oncology Inc / ACORN BIOVENTURES, L.P. - CARDIFF ONCOLOGY, INC. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* CARDIFF ONCOLOGY, INC. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 14147L108 (CUSIP Number) Acorn Bioventures, L.P. Attention: Anders Hove 420 Lexington Avenue Suite 2626 New York, New York 10170 (212) 299- |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 Cardiff Oncology, Inc. |
|
| November 3, 2022 |
Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates –Data from Phase 1b/2 trial in KRAS-mutated metastatic colorectal cancer (mCRC), per September 12th announcement, show durable responses to treatment and support initiation of ONSEMBLE, a randomized Phase 2 trial in KRAS/NRAS-mutated mCRC –Cash, cash equivalents, and short-term investments of approximately $114 million as of September 30, 2022, provide projected runway into 2025 SAN DIEGO, November 3, 2022 – Cardiff Oncology, Inc. |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CAR |
|
| October 3, 2022 |
Company Overview The Onvansertib Opportunity S G2 G1 M Irinotecan Taxanes S G2 G1 M G2 G1 M S PLK1 plays multiple roles during cell cycle S-Phase G2/M Checkpoint M-Phase G1 M S G2 PLK1 plays multiple roles during cell cycle S-Phase G2/M Checkpoint M-Phase G2 G1 S M PLK1 plays multiple roles during cell cycle S-Phase G2/M Checkpoint M-Phase ONVANSERTIB INHIBITS PLK1 ? ? ? SPECIFICITYPROPERTIES WHAT WHY WHERE WHAT WHY WHERE 1st LINE 2nd LINENormal Mutated 2nd LINE HISTORICAL ORR 5% 11. |
|
| October 3, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2022 Cardiff Oncology, Inc. |
|
| September 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2022 Cardiff Oncology, Inc. |
|
| September 12, 2022 |
Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022 Durable responses to treatment, with a median duration of response (mDoR) of 11. |
|
| September 12, 2022 |
Clinical and Corporate Update SEPTEMBER 12, 2022 2 Forward-looking statements CERTAIN STATEMENTS IN THIS PRESENTATION ARE FORWARD-LOOKING within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| September 12, 2022 |
Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates Next trial in RAS-mutated mCRC (ONSEMBLE) is a randomized Phase 2 trial to demonstrate onvansertib?s contribution to SoC and position for a possible accelerated approval opportunity; topline data expected in 2H 2024 Data from ongoing Phase 1b/2 trial in KRAS-mutated mCRC show durable responses to treatment, with a median duration of response (mDoR) of 11. |
|
| September 6, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2022 Cardiff Oncology, Inc. |
|
| September 6, 2022 |
Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022 Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022 SAN DIEGO, September 6, 2022 ? Cardiff Oncology, Inc. |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CARDIFF |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Cardiff Oncology, Inc. |
|
| August 4, 2022 |
Cardiff Oncology Reports Second Quarter 2022 Results and Provides Business Updates Cardiff Oncology Reports Second Quarter 2022 Results and Provides Business Updates ?Initial preclinical data in ovarian cancer presented at AACR showed treatment with onvansertib plus olaparib leading to a statistically significant survival benefit compared to treatment with either agent alone ?Data from Phase 2 metastatic castration-resistant prostate cancer (mCRPC) clinical trial presented at AA |
|
| July 12, 2022 |
As filed with the U.S. Securities and Exchange Commission on July 12, 2022 As filed with the U.S. Securities and Exchange Commission on July 12, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cardiff Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 27-2004382 (State or other jurisdiction IRS Employer of incorporation or organiza |
|
| July 12, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) CARDIFF ONCOLOGY, INC. |
|
| June 14, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 Cardiff Oncology, Inc. |
|
| June 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 Cardiff Oncology, Inc. |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CARDIFF |
|
| May 5, 2022 |
Cardiff Oncology Reports First Quarter 2022 Results and Provides Business Updates Cardiff Oncology Reports First Quarter 2022 Results and Provides Business Updates ?Reported new Phase 1b/2 data from lead KRAS-mutated metastatic colorectal cancer (mCRC) clinical program showing objective response rate and median progression-free survival that substantially exceed those recorded in historical control trials ?Announced new data from Phase 2 metastatic castration-resistant prostate |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 Cardiff Oncology, Inc. |
|
| April 21, 2022 |
Cardiff Oncology, Inc. 11055 Flintkote Avenue San Diego, CA 92121 April 21, 2022 Cardiff Oncology, Inc. 11055 Flintkote Avenue San Diego, CA 92121 April 21, 2022 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Doris Gama Re: Cardiff Oncology, Inc. Form S-3 File No. 333-264148 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the ?Act?), Ca |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 12, 2022 |
Cardiff Oncology Announces Departure of Chief Medical Officer Cardiff Oncology Announces Departure of Chief Medical Officer SAN DIEGO, April 12, 2022 ? Cardiff Oncology, Inc. |
|
| April 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2022 Cardiff Oncology, Inc. |
|
| April 8, 2022 |
Cardiff Oncology Announces Data Showing the Combination of PARP Inhibition with Onvansertib Overcomes PARP Inhibitor Resistance in BRCA1-mutant and Wildtype Patient-Derived Xenograft Ovarian Cancer Models ?Combining onvansertib with the PARP inhibitor (PARPi) olaparib led to statistically significant survival benefits compared to treatment with either agent alone in PARPi-resistant ovarian cancer models ?Onvansertib-olaparib combination was well tolerated in vivo SAN DIEGO, April 8, 2022 ? Cardiff Oncology, Inc. |
|
| April 8, 2022 |
Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting ?Trial evaluates onvansertib in combination with abiraterone and prednisone in metastatic castration-resistant prostate cancer (mCRPC) patients showing initial abiraterone resistance by rising PSA ?Disease control increased with increasing |
|
| April 8, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2022 Cardiff Oncology, Inc. |
|
| April 5, 2022 |
Form of Subordinated Indenture Exhibit 4.4 CARDIFF ONCOLOGY, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee's Certific |
|
| April 5, 2022 |
EX-4.3 2 a43ex040522.htm EX-4.3 Exhibit 4.3 CARDIFF ONCOLOGY, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 3 Section 2.1 Designation and Terms of Securities 3 Section 2.2 Form of Securitie |
|
| April 5, 2022 |
As filed with the U.S. Securities and Exchange Commission on April 5, 2022 As filed with the U.S. Securities and Exchange Commission on April 5, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cardiff Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 27-2004382 (State or other jurisdiction IRS Employer of incorporation or organiza |
|
| April 5, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) CARDIFF ONCOLOGY, INC. |
|
| February 24, 2022 |
Cardiff Oncology Reports Fourth Quarter and Full Year 2021 Results and Recent Highlights Cardiff Oncology Reports Fourth Quarter and Full Year 2021 Results and Recent Highlights ?Phase 1b/2 trial in lead KRAS-mutated metastatic colorectal cancer program continues to show an objective response rate and median progression-free survival that substantially exceed those seen in historical control trials ?Received $15 million equity investment from Pfizer through the Pfizer Breakthrough Growth Initiative ?Adam Schayowitz, Ph. |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 Cardiff Oncology, Inc. |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-35558 CARDIFF ONCOLOGY, |
|
| February 14, 2022 |
CRDF / Cardiff Oncology Inc / CAXTON CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
CRDF / Cardiff Oncology Inc / Corriente Advisors, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cardiff Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 14147L108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 14, 2022 |
EXHBIIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the shares of common stock, par value $0. |
|
| February 14, 2022 |
CRDF / Cardiff Oncology Inc / Avidity Partners Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 31, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2022 Cardiff Oncology, Inc. |
|
| January 31, 2022 |
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, January 31, 2022 - Cardiff Oncology, Inc. |
|
| January 18, 2022 |
Cardiff Oncology Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival ?12 of 35 (34%) patients treated per protocol at the recommended Phase 2 dose (RP2D) in combination with FOLFIRI and bevacizumab achieved a complete response or partial response (CR: 1 patient; PR: 11 patients) ?17 of 48 (35%) patients across all dose levels achieved a CR or PR. |
|
| January 18, 2022 |
Onvansertib Ph 1b/2 mCRC Trial Data Update Mark Erlander, Ph.D. Chief Executive Officer 20222021 2008 2013 2017 20222021 2008 2013 2017 ? ? ? 1st LINE 2nd LINE 2nd LINE HISTORICAL ORR 5% 11.4% 13% 91.1% Onvansertib DOWNSTREAM S G2 G1 M Katherine Ruffner, MD Chief Medical Officer WEEKS 1?2 WEEKS 3?4 WEEKS 1?2 WEEKS 3?4 1 2 3 WEEKS 1?2 WEEKS 3?4 HISTORICAL ORR* 5% 11.4% 13% HISTORICAL mPFS* 4.5?5.7 |
|
| January 18, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 Cardiff Oncology, Inc. |
|
| January 11, 2022 |
Cardiff Oncology Appoints Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, RPh, as Senior Vice President, Regulatory Affairs ?Dr. Smeal has over 20 years of industry experience developing targeted therapies and previously served as CSO of Cancer Biology at Eli Lilly and Company, and director of Pfizer Oncology Research Unit ?Mr. Monahan is a registered pharmacist with over 20 yea |
|
| January 11, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 Cardiff Oncology, Inc. |
|
| December 10, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2021 Cardiff Oncology, Inc. |
|
| December 10, 2021 |
Cardiff Oncology Announces Upcoming Presentation on Lead KRAS-mutated Metastatic Colorectal Cancer Program at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium SAN DIEGO, December 10, 2021 - Cardiff Oncology, Inc. |
|
| December 3, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2021 Cardiff Oncology, Inc. |
|
| December 3, 2021 |
Cardiff Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Cardiff Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, December 3, 2021 - Cardiff Oncology, Inc. |
|
| November 19, 2021 |
CRDF / Cardiff Oncology Inc / PFIZER INC - SC 13G CARDIFF ONCOLOGY INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.)* Cardiff Oncology, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 14147L108 (CUSIP Number) November 18, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| November 18, 2021 |
CALCULATION OF REGISTRATION FEE CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered (1) Proposed Maximum Aggregate Offering Price per share (1) Aggregate Maximum Offering Price (1) Amount of Registration Fee (2) Common stock, par value $0. |
|
| November 18, 2021 |
Securities Purchase Agreement dated November 17, 2021 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of November 17, 2021, between Cardiff Oncology, Inc., a corporation organized under the laws of the State of Delaware (the ?Company?), and Pfizer Inc., a corporation organized under the laws of the State of Delaware (the ?Purchaser?). WHEREAS, subject to the terms and conditions set forth i |
|
| November 18, 2021 |
Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative ?Pfizer invests $15 million in Cardiff Oncology common shares ?Adam Schayowitz, Ph. |
|
| November 18, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2021 Cardiff Oncology, Inc. |
|
| November 10, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 Cardiff Oncology, Inc. |
|
| November 10, 2021 |
Cardiff Oncology to Present at Upcoming Jefferies London Healthcare and Piper Sandler 33rd Annual Investor Conferences SAN DIEGO, November 9, 2021 - Cardiff Oncology, Inc. |
|
| November 4, 2021 |
Cardiff Oncology Reports Third Quarter 2021 Results and Provides Business Updates Cardiff Oncology Reports Third Quarter 2021 Results and Provides Business Updates ?Announced updated clinical data from lead KRAS-mutated metastatic colorectal cancer program showing an objective response rate and median progression free survival that substantially exceed those seen in historical control trials ?Strengthened management team with the appointments of Katherine L. |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 Cardiff Oncology, Inc. |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CAR |
|
| September 8, 2021 |
New Data Presentation: KRAS-mutated Metastatic Colorectal Cancer (mCRC) September 8, 2021 2021 Corporation Presentation I 2 Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| September 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2021 Cardiff Oncology, Inc. |
|
| September 8, 2021 |
EX-99.1 2 a991ex090821.htm EX-99.1 Cardiff Oncology Announces New Data from Phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival –8 of 19 (42%) patients treated per protocol at the recommended Phase 2 dose (RP2D) of onvansertib 15 mg/m2 who were evaluable for disease response as of the data cut-off achieved a partial res |
|
| September 7, 2021 |
Cardiff Oncology to Present at Upcoming Investor Conferences in September Cardiff Oncology to Present at Upcoming Investor Conferences in September SAN DIEGO, September 7, 2021 - Cardiff Oncology, Inc. |
|
| September 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2021 Cardiff Oncology, Inc. |
|
| August 25, 2021 |
Cardiff Oncology to Present New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer on September 8, 2021 SAN DIEGO, August 25, 2021 - Cardiff Oncology, Inc. |
|
| August 25, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2021 Cardiff Oncology, Inc. |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CARDIFF |
|
| August 5, 2021 |
Cardiff Oncology Reports Second Quarter 2021 Results and Provides Business Updates ?Lead clinical program of onvansertib in KRAS-mutated metastatic colorectal cancer continues to generate data showing robust response to treatment and progression-free survival ?First patient dosed in Phase 2 study of onvansertib in combination with standard-of-care for the treatment of metastatic pancreatic ductal adenocarcinoma ?Newly appointed CMO and CFO, and shareholders elected two new members to Company?s Board of Directors, with expertise in drug development, financial strategy, and business development SAN DIEGO (August 5, 2021) ? Cardiff Oncology, Inc. |
|
| August 5, 2021 |
EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is made and entered into effective as of August 4, 2021 (the ?Effective Date?), by and between Katherine L. |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 Cardiff Oncology, Inc. |
|
| July 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2021 Cardiff Oncology, Inc. |
|
| July 12, 2021 |
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer ?Dr. Ruffner is a US-trained hematologist/oncologist with over 25 years of clinical care, oncology biotechnology and pharmaceutical drug development experience ?Mr. Levine has over 20 years of corporate and investment banking experience in the biotechno |
|
| July 12, 2021 |
Employment Agreement dated July 12, 2021 by and between James Levine and Cardiff Oncology, Inc. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is made and entered into effective as of July 12, 2021 (the ?Effective Date?), by and between James Levine (the ?Executive?) and Cardiff Oncology, Inc. |
|
| July 6, 2021 |
Cardiff Oncology to Participate in a Fireside Chat at the William Blair Biotech Focus Conference 2021 SAN DIEGO (July 6, 2021) ? Cardiff Oncology, Inc. |
|
| July 6, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2021 Cardiff Oncology, Inc. |
|
| June 28, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2021 Cardiff Oncology, Inc. |
|
| June 28, 2021 |
Cardiff Oncology Added to the Russell 2000? and other FTSE Russell Indexes SAN DIEGO (June 28, 2021) ? Cardiff Oncology, Inc. |
|
| June 10, 2021 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 Cardiff Oncology, Inc. |
|
| June 10, 2021 |
As filed with the U.S. Securities and Exchange Commission on June 10, 2021 As filed with the U.S. Securities and Exchange Commission on June 10, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cardiff Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 27-2004382 (State or other jurisdiction IRS Employer of incorporation or organiza |
|
| June 10, 2021 |
Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of Directors ?Mani Mohindru, Ph. |
|
| June 8, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2021 Cardiff Oncology, Inc. |
|
| June 8, 2021 |
EX-99.1 2 a991ex060821.htm EX-99.1 Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic Cancer •Trial represents a key component of onvansertib’s KRAS-targeted clinical programs and is designed to leverage the synergy of onvansertib when combined with irinotecan/5-FU •The first patient was dosed at the Mayo Clinic Ca |
|
| June 1, 2021 |
Turning the Tide on Cancer June 2021 2021 Corporation Presentation I 2 Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| June 1, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 Cardiff Oncology, Inc. |
|
| May 20, 2021 |
Cardiff Oncology to Present at the Jefferies Virtual Healthcare Conference SAN DIEGO (May 20, 2021) ? Cardiff Oncology, Inc. |
|
| May 20, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 Cardiff Oncology, Inc. |
|
| May 6, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-35558 CARDIFF |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 Cardiff Oncology, Inc. |
|
| May 6, 2021 |
Cardiff Oncology Announces First Quarter 2021 Results and Recent Highlights SAN DIEGO (May 6, 2021) ? Cardiff Oncology, Inc. |
|
| April 28, 2021 |
DEFA14A 1 a2021defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as per |
|
| April 28, 2021 |
our definitive Proxy Statement on Schedule 14a for our 202 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 12, 2021 |
Key Opinion Leader Webinar Onvansertib for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer 2020 Corporation Presentation I 220 Corporation Pr sentation I 2 Forward-Looking Statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| April 12, 2021 |
Cardiff Oncology in Collaboration with MIT Presents Gene Signature Analyses Data Identifying Androgen-Independent Mechanism for Onvansertib-Abiraterone Synergy in mCRPC ?Onvansertib and the androgen receptor (AR) signaling inhibitor abiraterone synergize in an AR-independent manner in in-vitro and in-vivo metastatic castrate-resistant prostate cancer (mCRPC) models ?AR-independent effects of abira |
|
| April 12, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2021 Cardiff Oncology, Inc. |
|
| April 12, 2021 |
Cardiff Oncology Presents Findings from its Expanded Access Program Highlighting the Clinical Benefit of Onvansertib in Heavily Pretreated Patients with Metastatic KRAS-Mutated mCRC ?Evaluable participants (n=20) are heavily pretreated (median of 3 prior lines of treatment); an increase in progression-free survival is a desired outcome ?Median progression free survival (mPFS) is 5. |
|
| April 12, 2021 |
Cardiff Oncology Announces Onvansertib Phase 1b/2 Data that Continues to Demonstrate Robust Response to Treatment and Progression-Free Survival in KRAS-Mutated mCRC ?7 of 18 (39%) evaluable patients in the Phase 1b/2 trial have achieved a partial response to-date ?Evaluable patients have a median progression free survival (mPFS) of 9. |
|
| April 8, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2021 Cardiff Oncology, Inc. |
|
| April 8, 2021 |
Cardiff Oncology to Host Key Opinion Leader Webinar on Onvansertib for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer ?Virtual event will take place on Monday, April 12, 2021 at 11 a. |
|
| March 12, 2021 |
Form of Subordinated Indenture Exhibit 4.4 CARDIFF ONCOLOGY, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee's Certific |
|
| March 12, 2021 |
Exhibit 4.3 CARDIFF ONCOLOGY, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 3 Section 2.1 Designation and Terms of Securities 3 Section 2.2 Form of Securities and Trustee's Certificate 5 Se |
|
| March 12, 2021 |
OPEN MARKET SALE AGREEMENT1 March 12, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Cardiff Oncology, Inc. |
|
| March 12, 2021 |
As filed with the U.S. Securities and Exchange Commission on March 12, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cardiff Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 27-2004382 (State or other jurisdiction IRS Employer of incorporation or organiz |
|
| March 11, 2021 |
Cardiff Oncology to Present at the Oppenheimer 31st Annual Healthcare Conference SAN DIEGO (March 11, 2021) ? Cardiff Oncology, Inc. |
|
| March 11, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2021 Cardiff Oncology, Inc. |
|
| March 11, 2021 |
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2021 SAN DIEGO (March 10, 2021) – Cardiff Oncology, Inc. |
|
| March 3, 2021 |
Cardiff Oncology to Present at H.C. Wainwright Global Life Sciences Conference SAN DIEGO (March 3, 2021) – Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, today announ |
|
| March 3, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2021 Cardiff Oncology, Inc. |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 Cardiff Oncology, Inc. |
|
| February 25, 2021 |
EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is made and entered into effective as of February 22, 2021 (the ?Effective Date?), by and between Vicki Kelemen (the ?Executive?) and Cardiff Oncology, Inc. |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-35558 CARDIFF ONCOLOGY, |
|
| February 25, 2021 |
Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights SAN DIEGO (February 25, 2021) – Cardiff Oncology, Inc. |
|
| February 25, 2021 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.9 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the ?Agreement?) is made and entered into effective as of February 22, 2021 (the ?Effective Date?), by and between Mark Erlander (the ?Executive?) and Cardiff Oncology, Inc., a Delaware corporation (the ?Company?). R E C I T A L S WHEREAS, Executive serves as the Chief Executive Officer of the Co |
|
| February 25, 2021 |
Exhibit 10.17 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is made and entered into effective as of February 22, 2021 (the ?Effective Date?), by and between Brigitte Lindsay (the ?Executive?) and Cardiff Oncology, Inc., a Delaware corporation (the ?Company?). R E C I T A L S WHEREAS, Executive serves as the Vice President, Finance of the Company; and WHEREAS, in order to provid |
|
| February 24, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2021 Cardiff Oncology, Inc. |
|
| February 24, 2021 |
Cardiff Oncology to Participate in Gastrointestinal (GI) Oncology and Pancreatic Cancer Panel Discussion at the Cowen 41st Annual Health Care Conference SAN DIEGO (February 24, 2021) – Cardiff Oncology, Inc. |
|
| February 16, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2021 Cardiff Oncology, Inc. |
|
| February 16, 2021 |
EX-99.A EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the shares of common stock, par value $0.0001 per share, of Cardiff Oncology, Inc. dated as of February 16, 2021 is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cardiff Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 14147L108 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designa |
|
| February 16, 2021 |
Cardiff Oncology to Present at the LifeSci Partners Precision Oncology Day SAN DIEGO (February 16, 2021) – Cardiff Oncology, Inc. |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) CARDIFF ONCOLOGY, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 14147L108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 11, 2021 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2021 Cardiff Oncology, Inc. |
|
| February 11, 2021 |
Cardiff Oncology Presents Phase 2 mCRPC Trial Data Showing a Two-Fold Increase in Efficacy with an Optimized Onvansertib Dosing Schedule •Two-fold increase (29% to 63%) in disease control rate at 12 weeks (the trial’s primary efficacy endpoint) seen in patients receiving onvansertib for 14 days vs. |
|
| February 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CARDIFF ONCOLOGY, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 14147L108 (CUSIP Number) January 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 26, 2021 |
Cardiff Oncology Receives “Study May Proceed” from FDA to Initiate Phase 2 Trial of Onvansertib in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) •Trial will evaluate the safety and efficacy of onvansertib in combination with standard-of-care for second-line treatment of patients with metastatic PDAC who have failed first line treatment with a gemcitabine-based chemotherapy regimen SAN DIEGO (January 26, 2021) – Cardiff Oncology, Inc. |
|
| January 26, 2021 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2021 Cardiff Oncology, Inc. |
|
| January 15, 2021 |
Cardiff Oncology Presents Data that Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC and Initial Findings from its Expanded Access Program •Of the 12 Phase 1b patients evaluable for efficacy as of the ASCO-GI data cut-off date (November 1, 2020), 5 (42%) achieved a partial response (PR) and 8 (67%) have shown a durable response ranging from 6. |
|
| January 15, 2021 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2021 Cardiff Oncology, Inc. |
|
| December 21, 2020 |
Separation Agreement between Thomas Adams and Cardiff Oncology, Inc. dated December 21, 2020 Exhibit 10.1 SEPARATION AGREEMENT This Separation Agreement (“Agreement”) is made by and between Cardiff Oncology, Inc. (the “Company”) and Thomas Adams (“Employee”) (collectively the “Parties”). In consideration for the execution of this Agreement, and the performance of the terms and conditions set forth herein, the Parties agree as follows: 1.Separation Date. Employee’s employment with the Comp |
|
| December 21, 2020 |
Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board SAN DIEGO (December 21, 2020) – Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, today announced |
|
| December 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2020 Cardiff Oncology, Inc. |
|
| December 7, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2020 Cardiff Oncology, Inc. |
|
| December 7, 2020 |
Cardiff Oncology Presents Data at ASH Demonstrating the Safety and Anti-Leukemic Activity of Onvansertib in Patients with Relapsed/Refractory AML SAN DIEGO (December 6, 2020) – Cardiff Oncology, Inc. |
|
| November 23, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2020 Cardiff Oncology, Inc. |
